|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/26 | |
| A61K 38/16 | |||
| A61K 39/395 | |||
| C07K 16/22 | |||
| C07K 16/24 | |||
| C07K 16/28 |
| (11) | Number of the document | 2672986 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12744782.9 |
| Date of filing the European patent application | 2012-02-09 | |
| (97) | Date of publication of the European application | 2013-12-18 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/024452 |
| Date | 2012-02-09 |
| (87) | Number | WO 2012/109429 |
| Date | 2012-08-16 |
| (30) | Number | Date | Country code |
| 201161440918 P | 2011-02-09 | US |
| (72) |
KRANZ, James, US
RINELLA, Joseph, US
|
| (73) |
GlaxoSmithKline LLC,
251 Little Falls Drive, Wilmington, DE 19808,
US
|
| (54) | LYOPHILIZED FORMULATIONS |
| LYOPHILIZED FORMULATIONS |